Skip to main content

Research Repository

Advanced Search

Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ

Miligy, Islam M.; Toss, Michael S.; Gorringe, Kylie L.; Ellis, Ian O.; Green, Andrew R.; Rakha, Emad A.

Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ Thumbnail


Authors

Islam M. Miligy

Michael S. Toss

Kylie L. Gorringe

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

Aurora Kinase A (AURKA/STK15) has a role in centrosome duplication and is a regulator of mitotic cell proliferation. It is over-expressed in breast cancer and other cancers, however; its role in ductal carcinoma in situ (DCIS) remains to be defined. This study aims to characterize AURKA protein expression in DCIS and evaluate its prognostic significance. Methods: AURKA was assessed immunohistochemically in a large well-characterized cohort of DCIS (n = 776 pure DCIS and 239 DCIS associated with invasive breast cancer [DCIS-mixed]) with long-term follow-up data (median = 105 months) and basic molecular characterization. Results: High AURKA expression was observed in 15% of DCIS cases and was associated with features of aggressiveness including larger tumour size, high nuclear grade, hormone receptor negativity, HER2 positivity, and high Ki67 proliferation index. AURKA expression was higher in DCIS associated with invasive breast cancer than in pure DCIS (p < 0.0001). In the DCIS-mixed cohort, the invasive component showed higher AURKA expression than the DCIS component (p < 0.0001). Outcome analysis revealed that AURKA was a predictor of invasive recurrence (p = 0.002). Conclusion: High AURKA expression is associated with poor prognosis in DCIS and might be a potential marker to predict DCIS progression to invasive disease.

Citation

Miligy, I. M., Toss, M. S., Gorringe, K. L., Ellis, I. O., Green, A. R., & Rakha, E. A. (2022). Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 89(6), 382–392. https://doi.org/10.1159/000522244

Journal Article Type Article
Acceptance Date Jan 24, 2022
Online Publication Date May 9, 2022
Publication Date 2022-12
Deposit Date Feb 1, 2022
Publicly Available Date May 9, 2022
Print ISSN 1015-2008
Electronic ISSN 1423-0291
Publisher S. Karger AG
Peer Reviewed Peer Reviewed
Volume 89
Issue 6
Pages 382–392
DOI https://doi.org/10.1159/000522244
Keywords Cell Biology; Molecular Biology; General Medicine; Pathology and Forensic Medicine
Public URL https://nottingham-repository.worktribe.com/output/7371453
Publisher URL https://www.karger.com/Article/Abstract/522244
Additional Information This is the accepted manuscript version of an article published by S. Karger AG in Pathobiology 2022, Vol. 89, No. 6, https://doi.org/10.1159/000522244 available on https://www.karger.com/Article/FullText/522244